Clene To Start Testing CNM-ZnAg In COVID-19 Patients In Brazil

by Vandana Singh, Benzinga Editor

February 16, 2021 1:29 PM | 1 min read | Make a Comment

Regulatory authorities in Brazil signed off Clene Inc's (NASDAQ: CLNN) Phase 2 study evaluating CNM-ZnAg liquid solution in acutely symptomatic, non-hospitalized COVID-19 patients. CNM-ZnAg is a proprietary zinc-silver ionic solution.
The 276-subject trial's primary endpoint will evaluate the rate of decreased hospitalizations at day 28, with secondary endpoints assessing time to symptom resolution.
Enrollment will complete in mid-2021, with results expected in the second half of 2021.
Price Action: CLNN gained 13.2% at $14.14 in market trading hours on the last check Tuesday.

Posted In: Biotech News FDA General brazil Covid-19 Phase 2

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.